Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 8976 results

  1. Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 17 April 2026.

    Technology appraisal guidance
    In consultation

  2. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  3. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]

    Awaiting development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  7. Ectopic pregnancy and miscarriage

    In development Reference number: GID-QS10202 Expected publication date:  06 May 2026

    Quality standard
    In development

  8. STS101 for treating acute migraine [TSID11782]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. BioTime's Premvia HyStem hydrogel for the management of a wide range of wounds

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. MT660 CerebAir for monitoring continuous, real-time EEG

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation